We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

239 hedge funds and large institutions have $2.88B invested in Nektar Therapeutics in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 79 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 21

2% more funds holding

Funds holding: 235 → 239 (+4)

0.07% less ownership

Funds ownership: 6.22% → 6.15% (-0.07%)

5% less call options, than puts

Call options by funds: $11.1M | Put options by funds: $11.8M

6% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 79

15% less capital invested

Capital invested by funds: $3.39B → $2.88B (-$509M)

Holders
239
Holders Change
+4
Holders Change %
+1.7%
% of All Funds
4.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
74
Reduced
79
Closed
21
Calls
$11.1M
Puts
$11.8M
Net Calls
-$642K
Net Calls Change
-$1.34M

Top Buyers

1
CCM
Camber Capital Management
Massachusetts
+$27.7M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$12.1M
3
Millennium Management
Millennium Management
New York
+$8.64M
4
State Street
State Street
Massachusetts
+$6.81M
5
Two Sigma Investments
Two Sigma Investments
New York
+$5.57M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$36.6M
2
Ameriprise
Ameriprise
Minnesota
-$30.9M
3
First Trust Advisors
First Trust Advisors
Illinois
-$16.5M
4
BlackRock
BlackRock
New York
-$7.95M
5
PI
Putnam Investments
Massachusetts
-$7.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMU
176
Pictet Asset Management (UK)
United Kingdom
$199K -$57.3K -207 -21%
Aberdeen Group
177
Aberdeen Group
United Kingdom
$193K – – –
Rafferty Asset Management
178
Rafferty Asset Management
New York
$189K +$203K +733 New
JMPWA
179
JP Morgan Private Wealth Advisors
California
$187K -$3.88K -14 -2%
Cambridge Investment Research Advisors
180
Cambridge Investment Research Advisors
Iowa
$177K -$554 -2 -0.3%
SCM
181
Shelton Capital Management
Colorado
$176K – – –
OQS
182
Occudo Quantitative Strategies
Florida
$174K +$187K +674 New
CC
183
Centiva Capital
New York
$173K +$187K +674 New
SACTSONJ
184
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
$172K – – –
MCIA
185
Mountain Capital Investment Advisors
Colorado
$168K – – –
Simplex Trading
186
Simplex Trading
Illinois
$112K +$15.5K +56 +15%
CG
187
Cutler Group
California
$106K – – –
PNC Financial Services Group
188
PNC Financial Services Group
Pennsylvania
$102K -$1.94K -7 -2%
PAM
189
Panagora Asset Management
Massachusetts
$90K – – –
MCA
190
Mercer Capital Advisers
New Jersey
$86K – – –
PCM
191
Penserra Capital Management
California
$71K +$554 +2 +0.7%
S
192
SignatureFD
Georgia
$57K -$830 -3 -1%
SPIA
193
Steward Partners Investment Advisory
New York
$42K +$44.8K +162 New
IUHSA
194
Itau Unibanco Holding S.A.
Brazil
$33K +$35.7K +129 New
EVM
195
Eaton Vance Management
Massachusetts
$32K +$3.04K +11 +10%
CAPTRUST Financial Advisors
196
CAPTRUST Financial Advisors
North Carolina
$28K – – –
Baillie Gifford & Co
197
Baillie Gifford & Co
United Kingdom
$26K – – –
GWS
198
Glassman Wealth Services
Virginia
$21K +$5.81K +21 +34%
FF
199
FourThought Financial
Florida
$17K – – –
Northwestern Mutual Wealth Management
200
Northwestern Mutual Wealth Management
Wisconsin
$17K – – –
6 7
8
9 10

NKTR Hedge Fund Activity: Q2 2021 in Review

239 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2021, worth a combined $2.88B — down 15% from $3.39B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new NKTR positions and 21 closed out — a net gain of 4 holders — while 74 added to existing stakes and 79 trimmed.

The largest buyer was Camber Capital Management, adding an estimated $27.7M. The largest seller was Fidelity Investments, cutting an estimated $36.6M.

  • 239 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2021, up from 235 in Q1 2021.
  • Funds reported $2.88B of Nektar Therapeutics stock for Q2 2021, down 15% quarter-over-quarter.
  • 25 funds opened new Nektar Therapeutics positions in Q2 2021 and 21 closed out, a net change of +4 holders.
  • The largest Nektar Therapeutics buyer in Q2 2021 was Camber Capital Management, an estimated $27.7M added.
  • The largest Nektar Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $36.6M sold.

Based on aggregated 13F filings for Q2 2021.